An interventional study of Wide Circumferential Pulmonary Vein Antrum Isolation (PVAI) and Pulmonary Vein Antrum Isolation Plus Driver Ablation (PVAI+drivers) in Atrial Fibrillation, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Active, not recruiting at 32 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 318 studies in Atrial Fibrillation with a site in Canada — 50 open to participants now, 73 under way, 8 of them phase 3. Atrial Fibrillation · Canada.
Among the 318 studies in Atrial Fibrillation with a site in Canada, this one is the 75th largest by enrollment of the 261 interventional ones that give a count, is one of 15 that started in 2021, is one of 135 with no phase, reaches primary completion later than 35 of the 72 other live ones, and was the 230th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →50 of the 318 studies in Atrial Fibrillation with a site in Canada are open now. Recruiting first, the newest first:
Milestone Pharmaceuticals Inc. · Sites in Canada, United States, Netherlands
Ages 18+
Regeneron Pharmaceuticals · Sites in Canada, United States, Japan
Ages 18+
Pavel Antiperovitch · Sites in Canada
Ages 18+
French Cardiology Society · Sites in Canada, France, New Zealand
Ages 18+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
318 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 29 · Phase 3 64 · Phase 4 30
First in 1999; this study’s year is marked. 15 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 617 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 282 across the 261 interventional studies, 297 across the 57 observational. Of the 217 that completed or were terminated, 81 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
128 of 318 have an industry lead sponsor. The 10 most frequent:
McGill University Health Centre/Research Institute of the McGill University Health Centre is the lead sponsor of 422 studies on the registry; 106 are open to participants now.
McGill University Health Centre/Research Institute of the McGill University Health Centre has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
24 of the studies in Atrial Fibrillation with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT02150902Ottawa Heart Institute Research CorporationAugmented Wide Area Circumferential Catheter Ablation for Reduction of Atrial Fibrillation Recurrence | 2026-11-27 |
| NCT07245147Jacqueline JozaREDO-AF: Randomized Evaluation of Dual Options for AF Re-intervention | 2026-12 |
| NCT06249269Ratika ParkashReversal of Atrial Substrate to Prevent Atrial Fibrillation Cohort Study | 2026-12 |
| NCT05600829University of CalgaryA Behavioural Weight Loss Intervention Delivered in Cardiac Rehabilitation for Patients With Atrial Fibrillation and Obesity | 2026-12-30 |
Add all 24 to your calendar (.ics) → With an account.
Among the 318 studies in Atrial Fibrillation with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to compare the efficacy of three different ablation strategies in patients with persistent AF:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PV antral isolation alone (PVAI)
Procedure: Wide Circumferential Pulmonary Vein Antrum Isolation (PVAI)
PV antral isolation plus ablation of drivers (PVAI+drivers)
Procedure: Pulmonary Vein Antrum Isolation Plus Driver Ablation (PVAI+drivers)
PV antral isolation plus isolation of LA posterior wall (PVAI+Box)
Procedure: Pulmonary Vein Antrum Isolation Plus Box Isolation of Posterior Wall (PVAI+box)
Standard PVI
Standard PVI + Ablation of drivers in LA and RA
Standard PVI + Electrical isolation of the posterior wall of the left atrium
Freedom from documented atrial arrhythmia ≥ 30 seconds at 18 months after one ablation procedure on or off antiarrhythmic medications (AAM).
Time frame: 18 months
Freedom from documented AF > 30 seconds at 18 months after one procedure on or off AAM
Time frame: 18 months
Freedom from documented AF > 30 seconds at 18 months after one or more procedures on or off AAM
Time frame: 18 months
Freedom from documented atrial arrhythmia > 30 seconds at 18 months after one or more procedures on or off AAM
Time frame: 18 months
Freedom from documented AF > 30 seconds at 18 months after one procedure off AAM
Time frame: 18 months
Freedom from documented atrial arrhythmia > 30 seconds at 18 months after one procedure off AAM
Time frame: 18 months
Freedom from documented AF > 30 seconds at 18 months after one or more procedures off AAM
Time frame: 18 months
Freedom from documented atrial arrhythmia > 30 seconds after one or more procedures off AAM
Time frame: 18 months
Freedom from documented symptomatic AF > 30 seconds at 18 months after one procedure on or off AAM
Time frame: 18 months
Freedom from documented symptomatic atrial arrhythmia > 30 seconds after one procedure on or off AAM
Time frame: 18 months
Each of the above success measures stratified by CHA2DS2-VASc score
Time frame: 18 months
Incidence of peri-procedural complications including stroke, PV stenosis, cardiac perforation, esophageal injury, phrenic nerve palsy, and death
Time frame: 18 months
Procedure duration
Time frame: 18 months
Fluoroscopy time (dose)
Time frame: 18 months
Radiofrequency time
Time frame: 18 months
Number of repeat procedures
Time frame: 18 months
Effect of each strategy on AF cycle length changes and AF termination
Time frame: 18 months
Correlation of acute AF termination on long-term procedural outcome
Time frame: 18 months
Quality of life measurements during follow-up using AFEQT questionnaire
AFEQT questionnaires will be used at baseline, 6, 12 and 18 months
Time frame: 6-12-18 months
Quality of life measurements during follow-up using SF12 questionnaires
SF36 questionnaires will be used at baseline, 6, 12 and 18 months
Time frame: 6-12-18 months
Change in AF burden post-ablation procedure (% of time in AF)
Time frame: 18 months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2021 (actual). Primary completion is estimated for Sep 2027, 75 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 75 months is above that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
McGill University Health Centre/Research Institute of the McGill University Health Centre →